Loading
Everything OnCo dates to 2016: 448 entries, 136 papers listed on people's pages, 121 papers, 80 landmarks and 47 trials reported. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
448 dated entries in OnCo fall in 2016: 136 papers listed on people's pages, 121 papers, 80 landmarks, 47 trials reported, 29 approvals, 14 companies founded, 8 regulatory events, 7 technologies, 3 journals founded, 2 laws and regulations and 1 guideline change.
Of those, 8 to the day, 1 to the month and 439 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The approvals rows on treatment records: region, year and indication.
Squamous NSCLC after platinum
Mild to moderate actinic keratosis of face and scalp with red-light PDT (Ameluz)
Oncaspar centralised 2016; Erwinase and native asparaginases national
Urothelial carcinoma (later withdrawn); NSCLC
Advanced RCC
v2: T790M for osimertinib; plasma testing (first liquid biopsy companion diagnostic)
ROS1-positive metastatic NSCLC
Hepatic veno-occlusive disease with renal or pulmonary dysfunction after HSCT, adults and children
Multiple myeloma in combination (Neofordex)
Unresectable or metastatic liposarcoma after anthracycline
Progressive non-functional lung and GI NETs
PET imaging in men with suspected prostate cancer recurrence based on elevated PSA
PET localisation of SSTR-positive neuroendocrine tumours (Ga-68 DOTATATE)
Extended-release injection for acute and delayed nausea and vomiting with moderately emetogenic or anthracycline-cyclophosphamide chemotherapy (Sustol)
First-line CLL (RESONATE-2)
Same
Advanced RCC with everolimus after anti-angiogenic therapy
Metastatic pancreatic adenocarcinoma after gemcitabine, with fluorouracil and leucovorin. EMA EPAR: https://www.ema.europa.eu/en/medicines/human/EPAR/onivyde-pegylated-liposomal
Metastatic adenocarcinoma of the pancreas after gemcitabine-based therapy, with fluorouracil and leucovorin (marketing authorisation 14 October 2016, orphan designation 2011); the...
High-dose conditioning before autologous HSCT in myeloma (Evomela)
Onivyde 2L after gemcitabine (2016); NALIRIFOX label 2025
EGFR-expressing locally advanced or metastatic squamous NSCLC with gemcitabine and cisplatin
Soft tissue sarcoma not curable by surgery or radiotherapy, with doxorubicin (accelerated approval). Withdrawn in 2019 after the ANNOUNCE trial
Locally advanced or metastatic non-small-cell lung cancer progressing after platinum-based chemotherapy, with docetaxel: not recommended.
BRCA-mutated advanced ovarian cancer after ≥2 chemotherapies (later narrowed)
Previously treated metastatic colorectal cancer. TA405, published 24 August 2016, recommends it within its marketing authorisation with the patient access scheme discount.
Metastatic colorectal cancer after available therapies. Lonsurf marketing authorisation issued 25 April 2016.
CLL with 17p deletion
PD-L1 expression to inform atezolizumab treatment in urothelial carcinoma (later NSCLC)
The regulatory events on treatment records: designations, filings, decisions, label changes and withdrawals, most of them carrying a full date.
First US generic imatinib launched
Breakthrough Therapy designation for pretreated metastatic TNBC
With fulvestrant after endocrine therapy (PALOMA-3)
First-line CLL
CLL with 17p deletion after ≥1 therapy: first BCL-2 inhibitor
Urothelial carcinoma after platinum (accelerated; later withdrawn)
NSCLC after platinum
Accelerated approval, gBRCA/sBRCA ovarian, ≥2 prior lines
The statutes, regulations, guidance and court rulings in the law index, dated to the year the instrument was made.
United States, statute.
European Union, regulation.
The dated NCCN and ESMO versions in the guideline history, with the rows each one added, removed or recategorised.
1 row added. Anchored to FDA approval of nivolumab with ipilimumab, September 2015 (accelerated) and CheckMate 067 overall-survival data.
The year reported on trial records, with the headline result the record gives.
Median radiographic progression-free survival 7.0 against 4.4 months (hazard ratio 0.64, 95 percent confidence interval 0.54 to 0.75, p<0.001) but overall survival 21.3 against 24...
Five-year event-free survival 79.6 percent with high-dose methotrexate against 75.2 percent with Capizzi methotrexate; dexamethasone benefited children aged 1 to 9 (five-year event...
OS 20.1 vs 20.0 months; no benefit.
Cognitive deterioration at 3 months 63.5% (SRS alone) vs 91.7% (SRS plus WBRT); no survival difference.
One-year overall survival 87.3 percent and two-year overall survival 82 percent after autologous transplant, with two-year progression-free survival 79.8 percent and one-year trans...
OS 7.5 vs 5.1 months; HR 0.70.
ORR 69%.
5-year biochemical or clinical failure-free survival 90.6% (60 Gy in 20) vs 88.3% (74 Gy in 37), non-inferior.
15-year all-cause mortality among five-year survivors fell from 12.4% (early 1970s) to 6.0% (1990s) as treatment exposures were reduced.
3-year EFS 61.6% vs 48.4%.
Median overall survival 11.0 against 9.8 months (hazard ratio 0.90, 95 percent confidence interval 0.76 to 1.06, p=0.213): not met.
Median progression-free survival 46 (radiotherapy) vs 39 months (temozolomide), no significant difference.
Six months of androgen suppression added to radiotherapy improved biochemical disease-free survival (hazard ratio 0.52, 95 percent confidence interval 0.41 to 0.66) and clinical pr...
Poor responders: EFS HR 0.98 for MAPIE vs MAP, more toxicity. Good responders: no EFS benefit from interferon.
Trastuzumab plus lapatinib produced objective responses in roughly a third of refractory HER2-amplified colorectal cancers.
Multiple graduations (veliparib-carboplatin, neratinib, pembrolizumab, MK-2206, T-DM1 plus pertuzumab, durvalumab plus olaparib, cemiplimab plus fianlimab); pembrolizumab's graduat...
Complete remission 49 percent with MATRix (methotrexate, cytarabine, thiotepa, rituximab) against 23 percent with methotrexate-cytarabine alone; two-year failure-free survival 76 p...
No overall survival benefit.
CR/CRi 80.7% vs 29.4%; OS 7.7 vs 6.7 months.
Five-year overall survival 44.1 percent with adjuvant S-1 against 24.4 percent with gemcitabine (hazard ratio 0.57, 95 percent confidence interval 0.44 to 0.72; p below 0.0001).
Objective response 31.8% after chemotherapy (part A) and 39.7% first line (part B).
Median overall survival 10.4 months (pembrolizumab 2 mg/kg) and 12.7 months (10 mg/kg) against 8.5 months with docetaxel; hazard ratios 0.71 and 0.61.
Objective response 56%, durable in most responders; similar in virus-positive and virus-negative tumours.
5-year OS 31.9% vs 16.3% (024); 19.4% vs 11.3% (189).
Median overall survival 15.2 months with chemoradiotherapy against 16.5 months with chemotherapy alone (hazard ratio 1.03, p 0.83); local progression 32 against 46 percent; erlotin...
OS 18.8 vs 16.1 months, HR 0.77.
5-year distant metastasis-free survival 94.7% without chemotherapy in clinical-high, genomic-low risk women.
OS 63.9 vs 51.4 months, HR 0.76.
Median overall survival 6.1 months with nanoliposomal irinotecan plus fluorouracil and folinic acid against 4.2 months with fluorouracil and folinic acid (hazard ratio 0.67, 95 per...
Median overall survival 13.8 against 9.6 months (hazard ratio 0.73), in both the intention-to-treat and PD-L1-expressing populations.
PFS HR 0.56; OS HR 0.96 (NS).
15-year prostate-cancer mortality 3.1% (monitoring), 2.2% (surgery), 2.9% (radiotherapy); no significant difference.
Quality-adjusted life-years 46.4 vs 41.7 days; overall survival 9.2 vs 8.5 weeks; no meaningful benefit from whole-brain radiotherapy.
3-year PFS 85.7% (ABVD) vs 84.4% (AVD); bleomycin safely omitted.
Lean body mass increased (about +1 to +1.5 kg vs placebo); handgrip strength unchanged.
Five-year disease-free survival 86.3 percent with 70 Gy in 28 fractions against 85.3 percent with 73.8 Gy in 41 fractions (hazard ratio 0.85, 95 percent confidence interval 0.64 to...
Abiraterone + ADT: OS HR 0.63 in mHSPC; docetaxel + ADT: OS HR 0.78. Prostate radiotherapy improved survival in low-volume metastatic disease; abiraterone improved survival in high...
Day-100 survival 38.2% with defibrotide against 25% in historical controls (propensity-adjusted difference 23%, P = .0109); complete response by day 100 25.5% against 12.5%.
Adding the clipped node to sentinel node dissection cut the false-negative rate from 10.1 to 1.4 percent (p=0.03); targeted axillary dissection gave 2.0 percent.
Ongoing pragmatic trial of risk-based versus annual screening.
The publication year on key paper records.
Haugen BR, Alexander EK, Bible KC, et al. Thyroid.
Gianni L, Pienkowski T, Im YH, et al. The Lancet Oncology.
Cardoso F, van't Veer LJ, Bogaerts J, et al. New England Journal of Medicine.
Notta F, Chan-Seng-Yue M, Lemire M, et al. Nature.
Johnson JA, Rash JA, Campbell TS, et al. Sleep medicine reviews.
Larsen EC, Devidas M, Chen S, et al. Journal of Clinical Oncology.
Byrd JC, Harrington B, O'Brien S, et al. New England Journal of Medicine.
James ND, Sydes MR, Clarke NW, et al. The Lancet.
Brown PD, Jaeckle K, Ballman KV, et al. JAMA.
Temel JS, Abernethy AP, Currow DC, et al. The Lancet Oncology.
Armstrong AJ, Halabi S, Eisen T, et al. The Lancet Oncology.
Brown TJ, Brennan MC, Li M, et al. JAMA Oncology.
Fehrenbacher L, Spira A, Ballinger M, et al. The Lancet.
Kaufman HL, Russell J, Hamid O, et al. The Lancet Oncology.
Javle M, Bekaii-Saab T, Jain A, et al. Cancer.
Villani A, Shore A, Wasserman JD, et al. The Lancet Oncology.
Alvarnas JC, Le Rademacher J, Wang Y, et al. Blood.
Ogitani Y, Hagihara K, Oitate M, et al. Cancer science.
Loomis D, Guyton KZ, Grosse Y, et al. The Lancet Oncology.
Chen Q, Boire A, Jin X, et al. Nature.
Turtle CJ, Hanafi LA, Berger C, et al. Journal of Clinical Investigation.
Ferris RL, Blumenschein G, Fayette J, et al. New England Journal of Medicine.
Chen W, Zheng R, Baade PD, et al. CA: A Cancer Journal for Clinicians.
Dearnaley D, Syndikus I, Mossop H, et al. The Lancet Oncology.
Tie J, Wang Y, Tomasetti C, et al. Science Translational Medicine.
Ascierto PA, McArthur GA, Dréno B, et al. The Lancet Oncology.
Aparicio AM, Shen L, Tapia ELN, et al. Clinical Cancer Research.
Marina NM, Smeland S, Bielack SS, et al. The Lancet Oncology.
Cancer Genome Atlas Research Network, Linehan WM, Spellman PT, et al. New England Journal of Medicine.
Buchbinder EI, Desai A. American journal of clinical oncology.
Planchard D, Besse B, Groen HJM, et al. The Lancet Oncology.
Dimopoulos MA, Oriol A, Nahi H, et al. New England Journal of Medicine.
Campbell JD, Alexandrov A, Kim J, et al. Nature Genetics.
Beltran H, Prandi D, Mosquera JM, et al. Nature Medicine.
Ogitani Y, Aida T, Hagihara K, et al. Clinical Cancer Research.
Sartore-Bianchi A, Trusolino L, Martino C, et al. The Lancet Oncology.
Gotlib J, Kluin-Nelemans HC, George TI, et al. New England Journal of Medicine.
Baylin SB, Jones PA. Cold Spring Harbor perspectives in biology.
Feinberg AP, Koldobskiy MA, Göndör A. Nature reviews. Genetics.
Schöffski P, Chawla S, Maki RG, et al. The Lancet.
Ramsey SD, Bansal A, Fedorenko CR, et al. Journal of Clinical Oncology.
Altman BJ, Stine ZE, Dang CV. Nature Reviews Cancer.
Shain AH, Bastian BC. Nature Reviews Cancer.
Jin X, Ruiz Beguerie J, Sze DM, et al. The Cochrane database of systematic reviews.
Zhang L, Huang Y, Hong S, et al. The Lancet.
Bailey P, Chang DK, Nones K, et al. Nature.
Bonilla X, Parmentier L, King B, et al. Nature Genetics.
Giannakis M, Mu XJ, Shukla SA, et al. Cell Reports.
Richman SD, Southward K, Chambers P, et al. Journal of Pathology.
Telli ML, Timms KM, Reid J, et al. Clinical Cancer Research.
Bennett MH, Feldmeier J, Hampson NB, et al. The Cochrane database of systematic reviews.
Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K (IARC Handbook Working Group). New England Journal of Medicine.
Ferreri AJ, Cwynarski K, Pulczynski E, et al. The Lancet Haematology.
Royer B, Minvielle S, Diouf M, et al. Journal of Clinical Oncology.
Sankaranarayanan R, Prabhu PR, Pawlita M, et al. The Lancet Oncology.
Pritchard CC, Mateo J, Walsh MF, et al. New England Journal of Medicine.
Kantarjian HM, DeAngelo DJ, Stelljes M, et al. New England Journal of Medicine.
Mlecnik B, Bindea G, Angell HK, et al. Immunity.
Kumar S, Paiva B, Anderson KC, et al. The Lancet Oncology.
Herbst RS, Baas P, Kim DW, et al. The Lancet.
Reck M, Rodríguez-Abreu D, Robinson AG, et al. New England Journal of Medicine.
Bournet B, Muscari F, Buscail C, et al. Clinical and Translational Gastroenterology.
Hammel P, Huguet F, van Laethem JL, et al. JAMA.
Paice JA, Portenoy R, Lacchetti C, et al. Journal of Clinical Oncology.
Shin ES, Seo KH, Lee SH, et al. The Cochrane database of systematic reviews.
Hassan R, Thomas A, Alewine C, et al. Journal of Clinical Oncology.
Morello A, Sadelain M, Adusumilli PS. Cancer Discovery.
Awad MM, Oxnard GR, Jackman DM, et al. Journal of Clinical Oncology.
Massagué J, Obenauf AC. Nature.
Gebhart G, Lamberts LE, Wimana Z, et al. Annals of Oncology.
Ivey A, Hills RK, Simpson MA, et al. New England Journal of Medicine.
Gainor JF, Dardaei L, Yoda S, et al. Cancer Discovery.
Alexandrov LB, Ju YS, Haase K, et al. Science.
Zaretsky JM, Garcia-Diaz A, Shin DS, et al. New England Journal of Medicine.
Wang-Gillam A, Li CP, Bodoky G, et al. The Lancet.
Sturm D, Orr BA, Toprak UH, et al. Cell.
Mirza MR, Monk BJ, Herrstedt J, et al. New England Journal of Medicine.
Younes A, Santoro A, Shipp M, et al. The Lancet Oncology.
Morvan MG, Lanier LL. Nature Reviews Cancer.
Navari RM, Qin R, Ruddy KJ, et al. New England Journal of Medicine.
Tap WD, Jones RL, Van Tine BA, et al. The Lancet.
Finn RS, Martin M, Rugo HS, et al. New England Journal of Medicine.
Kleeff J, Korc M, Apte M, et al. Nature reviews. Disease primers.
Nghiem PT, Bhatia S, Lipson EJ, et al. New England Journal of Medicine.
Wang X, Teng F, Kong L, et al. OncoTargets and therapy.
Viardot A, Goebeler ME, Hess G, et al. Blood.
Richardson PG, Riches ML, Kernan NA, et al. Blood.
Sawada Y, Yoshikawa T, Ofuji K, et al. Oncoimmunology.
Tan BY, Acs G, Apple SK, et al. Histopathology.
Marinac CR, Nelson SH, Breen CI, et al. JAMA Oncology.
Hamdy FC, Donovan JL, Lane JA, et al. New England Journal of Medicine.
Carr NJ, Cecil TD, Mohamed F, et al. American Journal of Surgical Pathology.
Mulvenna P, Nankivell M, Barton R, et al. The Lancet.
Yao JC, Fazio N, Singh S, et al. The Lancet.
Johnson P, Federico M, Kirkwood A, et al. New England Journal of Medicine.
Armstrong GT, Chen Y, Yasui Y, et al. New England Journal of Medicine.
Lehmann BD, Jovanović B, Chen X, et al. PLoS One.
Brown CE, Alizadeh D, Starr R, et al. New England Journal of Medicine.
Shaw AT, Friboulet L, Leshchiner I, et al. New England Journal of Medicine.
Emile JF, Abla O, Fraitag S, et al. Blood.
Hortobagyi GN, Stemmer SM, Burris HA, et al. New England Journal of Medicine.
Buckner JC, Shaw EG, Pugh SL, et al. New England Journal of Medicine.
Koshiol J, Wozniak A, Cook P, et al. Cancer Medicine.
Siegel RL, Miller KD, Jemal A. CA: A Cancer Journal for Clinicians.
Morrow M, Van Zee KJ, Solin LJ, et al. Journal of Clinical Oncology.
Domingo E, Freeman-Mills L, Rayner E, et al. Lancet Gastroenterology and Hepatology.
Vale CL, Burdett S, Rydzewska LHM, et al. The Lancet Oncology.
Kumar A, Coleman I, Morrissey C, et al. Nature Medicine.
Steeg PS. Nature Reviews Cancer.
Baumert BG, Hegi ME, van den Bent MJ, et al. The Lancet Oncology.
Kalluri R. Nature Reviews Cancer.
Pavlova NN, Thompson CB. Cell metabolism.
Röhrig F, Schulze A. Nature Reviews Cancer.
Elmasry M, Lindop D, Dunne DF, et al. International Journal of Surgery.
Cabanillas ME, McFadden DG, Durante C. The Lancet.
Demetri GD, von Mehren M, Jones RL, et al. Journal of Clinical Oncology.
Scher HI, Morris MJ, Stadler WM, et al. Journal of Clinical Oncology.
Schnipper LE, Davidson NE, Wollins DS, et al. Journal of Clinical Oncology.
Chernet BT, Adams DS, Lobikin M, et al. Oncotarget.
Gronchi A, Strauss DC, Miceli R, et al. Annals of Surgery.
Roberts NJ, Norris AL, Petersen GM, et al. Cancer Discovery.
The history entries editors wrote on cancer records: the dated turning points of each disease.
Ductal carcinoma in situ (DCIS)
Neuroendocrine tumours
Non-small-cell lung cancer. Across 103 repeat biopsies, each ALK inhibitor is shown to select its own spectrum of resistance mutations, with G1202R rising after second-generation t...
High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL)
Philadelphia chromosome-like acute lymphoblastic leukaemia (Ph-like or BCR::ABL1-like ALL)
Brain metastases (secondary brain tumours). Brown and colleagues (JAMA): cognitive deterioration at three months in 63.5 percent with radiosurgery alone against 91.7 percent with a...
HER2-positive breast cancer with brain metastases
Muscle-invasive and advanced bladder cancer
Bladder & urothelial cancer
Bladder & urothelial cancer
Pancreatic ductal adenocarcinoma. 456 tumours, 32 genes, 10 pathways, squamous subtype worst. Liposomal irinotecan with fluorouracil: 6.1 versus 4.2 months after gemcitabine.
Small intestine cancer (small bowel adenocarcinoma). First randomised trial in resected small bowel adenocarcinoma (NCT02502370).
Colorectal cancer. Circulating tumour DNA after resection of stage II colon cancer gave a recurrence hazard ratio of 18 in 230 patients, the measurement every later trial of residu...
Renal cell carcinoma
Recurrent or metastatic head and neck squamous cell carcinoma
Localised prostate cancer, intermediate risk
ROS1-positive non-small-cell lung cancer
Neuroendocrine and small-cell prostate cancer
Liposarcoma
Osteosarcoma
Claudin 18.2-positive gastric cancer
NUT carcinoma (midline carcinoma with NUTM1 rearrangement). Birabresib (OTX015) and molibresib phase 1 cohorts.
Recurrent and metastatic nasopharyngeal carcinoma
Malignant peripheral nerve sheath tumour (MPNST)
Colorectal cancer. HERACLES treated RAS wild-type patients with HER2 amplification using trastuzumab and lapatinib and got responses in 8 of 27.
HER2-amplified colorectal cancer
Indolent and smouldering systemic mastocytosis
Vulvar cancer
Craniopharyngioma. KRANIOPHARYNGEOM 2007 shows radical resection with hypothalamic injury worsens quality of life without improving control.
Primary CNS lymphoma. Adding rituximab and thiotepa to methotrexate-cytarabine improves response and survival.
Prostate cancer. Pritchard found presumed deleterious germline DNA repair mutations in 11.8 percent of 692 men with metastatic prostate cancer, BRCA2 in 5.3 percent, with no relati...
Acute lymphoblastic leukaemia. CR/CRi 81% vs 29%; approval 2017.
Localised anal squamous cell carcinoma (stage I to III)
Early gastric cancer
PD-L1-high non-small-cell lung cancer without a driver mutation
Locally advanced unresectable pancreatic ductal adenocarcinoma
Mesothelioma
Systemic mastocytosis. Gotlib and colleagues (NEJM 2016); FDA approval April 2017.
Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia)
High-risk early HR-positive breast cancer
Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells
Head and neck squamous cell carcinoma
Relapsed and refractory classical Hodgkin lymphoma
NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia
Head and neck squamous cell carcinoma
Merkel cell carcinoma
Prostate cancer
Localised prostate cancer, very low and low risk
Appendiceal cancer and pseudomyxoma peritonei
Low-grade appendiceal mucinous neoplasm and pseudomyxoma peritonei
Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell)
Pancreatic ductal adenocarcinoma. Notta's whole genomes show chromothripsis and polyploidy, not stepwise mutation, in two-thirds of tumours, knocking out several drivers at once; B...
Brain metastases (secondary brain tumours)
Small intestinal neuroendocrine tumours
Lung neuroendocrine tumours (typical and atypical carcinoid)
Hodgkin lymphoma
Advanced-stage classical Hodgkin lymphoma (stage III to IV)
Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms. L, C, R, M and H groups (Emile et al., Blood 2016).
Rosai-Dorfman-Destombes disease
Erdheim-Chester disease
Astrocytoma, IDH-mutant (grades 2 to 4). Buckner and colleagues (NEJM) report median overall survival of 13.3 years against 7.8 years with radiotherapy alone.
Oligodendroglioma, IDH-mutant and 1p/19q-codeleted
Epithelioid haemangioendothelioma
Metastatic hormone-sensitive prostate cancer
Adrenocortical carcinoma
Prostate cancer. Methylation separates neuroendocrine from castration-resistant adenocarcinoma far more sharply than mutations do, in a pattern fitting divergent clonal evolution f...
Atypical teratoid/rhabdoid tumour (ATRT). Johann and Torchia (Cancer Cell) describe ATRT-TYR, ATRT-SHH and ATRT-MYC by methylation and expression.
Triple-negative breast cancer (TNBC). Lehmann refines the subtypes to four (BL1 35%, BL2 22%, M 25%, LAR 16%) with pCR 41% versus 18% versus 29%; Telli sets HRD score 42 in neoadju...
Chronic lymphocytic leukaemia
Chronic lymphocytic leukaemia. First BCL-2 inhibitor; RESONATE-2 moves ibrutinib to untreated CLL.
Relapsed or refractory chronic lymphocytic leukaemia
Astrocytoma, IDH-mutant (grades 2 to 4)
Oligodendroglioma, IDH-mutant and 1p/19q-codeleted
Glioma & glioblastoma
WNT-activated medulloblastoma
Brain and spinal cord tumours (all types). IDH mutation, 1p/19q codeletion and H3 K27M began to define brain tumour types alongside microscopy; extended in 2021.
Secondary and therapy-related acute myeloid leukaemia
Medulloblastoma
Diffuse midline glioma, H3 K27-altered (including DIPG). First histone-defined tumour entity.
Essential thrombocythaemia (ET). Marrow histology now distinguishes true ET from early myelofibrosis, which carries a worse outlook.
The since year on technology records: first use in humans or first approval, as the record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
The founded year on company records.
Boston, MA
Tel Aviv
Rotterdam
Rockville, Maryland
Boston, MA
Paris
Krakow, Poland
Shanghai
London
Oxford
New York, NY
New York, NY
Gaithersburg, Maryland
Budapest
The founded year on journal records.
American Society of Hematology
Elsevier
Elsevier
The selected publications each biography lists, which is a reading of that person rather than a reading of the year.
Radiation Oncology
NEJM
Oncology Reports
Journal of Nuclear Medicine
European Urology
Annals of Oncology
Case Reports in Oncological Medicine
Angewandte Chemie International Edition
Lancet Oncology
New England Journal of Medicine
New England Journal of Medicine
Gastroenterology
Journal of Clinical Oncology
Lancet Oncology
The Lancet
Annals of Oncology
NeuroImage: Clinical
The Lancet Oncology
Journal of Oncology Practice
Journal of Biological Chemistry
Einstein (São Paulo)
Endocrine-Related Cancer
JAMA Oncology
Lancet
Lancet Oncology
The Lancet Oncology
Journal of Clinical Oncology
Lancet
The Lancet Haematology
Nature Reviews Disease Primers
BMC Cancer
Infectious Agents and Cancer
Lancet Haematology
Molecular Cancer Research
Nat Cell Biol
Ocular Immunology and Inflammation
American Society of Clinical Oncology Educational Book
Therapeutic Advances in Medical Oncology
The Lancet Oncology
The Lancet Oncology
Lancet
NEJM
Annals of Surgery
Annals of the Rheumatic Diseases
JCO
JAMA Oncology
Cancer Cell
Blood
British Journal of Cancer
Clinical Cancer Research
Anticancer Research
Clinical Cancer Research
BMJ Open
Annals of Oncology
Lancet
PLOS Medicine
NEJM
Journal of Gastroenterology and Hepatology
Radiotherapy and Oncology
Lancet Oncology
Blood
Lancet Oncology
Nature Reviews Disease Primers
Cancer
Gastroenterology Research and Practice
The Lancet Oncology
Lancet Haematology
Nature
Radiotherapy and Oncology
Nature
Journal of Nuclear Medicine
Lancet Oncology
JCO
Journal of Clinical Oncology
Journal of Cranio-Maxillofacial Surgery
Journal of Clinical Oncology
Cancer Cytopathology
Nature Medicine
New England Journal of Medicine
NEJM
Journal of Cancer Research and Clinical Oncology
Nature
Breast Cancer Research and Treatment
The Lancet Oncology
Clinical Cancer Research
Annual Review of Pathology
Hematology
Cancer Cell
The Lancet. Gastroenterology & hepatology
Blood
Journal of Clinical Oncology
Cancer Research
NEJM
The Lancet Oncology
Lancet
NEJM
Nature
International Journal of Radiation Oncology, Biology, Physics
New England Journal of Medicine
Scientific Reports
Cancer
NEJM
Lancet
NEJM
Haematologica
Blood
JAMA Internal Medicine
Haematologica
Annals of Oncology
Acta Oncol
Head & Neck
Molecular Cancer Therapeutics
Quality of Life Research
Nature Reviews Cancer
Lancet Oncology
NEJM
New England Journal of Medicine
Lancet
Gynecologic Oncology
Sci Rep
Archives of Biochemistry and Biophysics
Hematology/Oncology Clinics of North America
New England Journal of Medicine
Journal of Clinical Oncology
Cancers
Int J Mol Sci
Eur J Cancer Care (Engl)
Nature
Deutsches Ärzteblatt international
OncoImmunology
Health Technology Assessment
Annual Review of Pharmacology and Toxicology
Modern Rheumatology
EMBO Journal
npj Genomic Medicine
Gastroenterology